var data={"title":"Stavudine: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Stavudine: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6986?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=stavudine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Stavudine: Patient drug information&quot;</a> and <a href=\"topic.htm?path=stavudine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Stavudine: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709417\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lactic acidosis and hepatomegaly with steatosis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination, including stavudine and other antiretrovirals. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine with other antiretroviral agents. Coadministration of stavudine and didanosine is contraindicated because of increased risk of serious and/or life-threatening events. Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pancreatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Fatal and nonfatal pancreatitis has occurred during therapy when stavudine was part of a combination regimen that included didanosine in both treatment-naive and treatment-experienced patients, regardless of degree of immunosuppression.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223021\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zerit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223022\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zerit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223061\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiretroviral, Reverse Transcriptase Inhibitor, Nucleoside (Anti-HIV)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223026\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>HIV-1 infection, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;60 kg: 30 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&ge;60 kg: 40 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> According to the Department and Health and Human Services (HHS) HIV treatment guidelines, the World Health Organization recommends 30 mg every 12 hours regardless of body weight (HHS [adult] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223044\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=stavudine-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Stavudine: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>HIV-1 infection, treatment:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates postnatal age (PNA) 0 to 13 days: 0.5 mg/kg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates PNA &ge;14 days: 1 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children weighing &lt;30 kg: 1 mg/kg/dose every 12 hours; maximum dose: 30 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents weighing 30 to &lt;60 kg: 30 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;60 kg: 30 mg every 12 hours (HHS [pediatric] 2016). <b>Note:</b> Manufacturer's labeling not recommended (40 mg) due to a greater incidence of adverse effects; pharmacokinetic data suggest toxicity may occur at this higher dose (HHS [pediatric] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223027\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Older patients should be closely monitored for signs and symptoms of peripheral neuropathy. Dosage should be carefully adjusted to renal function.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223028\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adults: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl &gt;50 mL/minute: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;60 kg: 30 mg every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;60 kg: 40 mg every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 26-50 mL/minute: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;60 kg: 15 mg every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;60 kg: 20 mg every 12 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CrCl 10-25 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;60 kg: 15 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;60 kg: 20 mg every 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis: Dialyzable (30%); Administer dose after hemodialysis on day of dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&lt;60 kg: 15 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;60 kg: 20 mg every 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Children: Specific recommendations not available. Reduction in dose or increase in dosing interval should be considered. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22560126\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222997\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zerit: 15 mg, 20 mg, 30 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 mg, 20 mg, 30 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zerit: 1 mg/mL (200 mL) [dye free; fruit flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (200 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222982\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11370380\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020412s040,020413s032lbl.pdf#page=28&amp;token=/ISgqU7XiPyLWUo0B94lzQB0CIYgG7NZoKRaPMdaHsXINMgIuP//9xcBdBqvbKktqUdrQ8+mCsFqemGpDS63njt/arDs8Vi1St5emnmqL7yZm0kLxi8vNZxdi/IdC3lB&amp;TOPIC_ID=9946\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020412s040,020413s032lbl.pdf#page=28</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223000\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered without regard to meals. Capsule may be opened and dispersed in a small amount of water; administer immediately (HHS [pediatric] 2016). Oral solution should be shaken vigorously prior to use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222998\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>HIV-1:</b> Treatment of HIV-1 infection in combination with other antiretroviral agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223069\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Stavudine may be confused with cetirizine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zerit may be confused with Zestril, Ziac, ZyrTEC</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222989\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse reactions reported below represent experience with combination therapy with other nucleoside analogues and protease inhibitors.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (25% to 46%), peripheral neuropathy (8% to 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash (18% to 30%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased amylase (21% to 31%; grades 3/4: 4% to 8%), increased gamma-glutamyl transferase (15% to 28%; grades 3/4: 2% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (43% to 53%), diarrhea (34% to 45%), vomiting (18% to 30%), increased serum lipase (27%; grades 3/4: 5% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hyperbilirubinemia (65% to 68%; grades 3/4: 7% to 16%), increased serum AST (42% to 53%; grades 3/4: 5% to 7%), increased serum ALT (40% to 50%; grades 3/4: 6% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anemia, anorexia, chills, diabetes mellitus, fever, hepatic failure, hepatitis, hepatomegaly with steatosis (some fatal), hyperglycemia, hyperlipidemia, hypersensitivity reaction, immune reconstitution syndrome, insomnia, insulin resistance, lactic acidosis (some fatal), leukopenia, lipoatrophy, lipotrophy, macrocytosis, myalgia, neutropenia, pancreatitis (some fatal), redistribution of body fat, severe weakness (severe neuromuscular weakness resembling Guillain-Barr&eacute;), thrombocytopenia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223003\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to stavudine or any component of the formulation; coadministration with didanosine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222986\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: <b>[US Boxed Warning]: Lactic acidosis and severe hepatomegaly with steatosis have been reported with nucleoside analogues, including fatal cases;</b> <b>coadministration</b><b> with didanosine is contraindicated</b>. Use with caution in patients with risk factors for liver disease (although acidosis has occurred in patients without known risk factors, risk may be increased with female gender, obesity, pregnancy, or prolonged exposure). Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or hepatotoxicity (transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Motor weakness: Severe motor weakness (resembling Guillain-Barr&eacute; syndrome) has been reported (including fatal cases, usually in association with lactic acidosis); manufacturer recommends discontinuation if motor weakness develops (with or without lactic acidosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: <b>[US Boxed Warning]: Pancreatitis (including some fatal cases) has occurred during combination therapy with didanosine. Coadministration with didanosine is contraindicated.</b> Suspend stavudine and any agents toxic to the pancreas in patients with suspected pancreatitis. If pancreatitis diagnosis is confirmed, use extreme caution if reinitiating stavudine; monitor closely and do not use didanosine in regimen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral neuropathy: May be treatment-limiting, especially with higher doses; use with caution in patients with pre-existing peripheral neuropathy, advanced HIV, and/or in combination with other medications known to cause neuropathy. Consider discontinuation of therapy if peripheral neuropathy develops; effect may be reversible if therapy discontinued immediately. Symptoms may worsen initially when therapy is discontinued.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Use with caution in patients with pre-existing bone marrow suppression.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; discontinue or interrupt therapy if worsening liver function occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Combination with didanosine or hydroxyurea: May increase risk of hepatotoxicity, pancreatitis, or severe peripheral neuropathy; lactic acidosis may also occur with concomitant didanosine administration. Use with hydroxyurea should be avoided; coadministration with didanosine is contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interferon alfa: Use with caution in combination with interferon alfa with or without ribavirin in HIV/HBV coinfected patients; monitor closely for hepatic decompensation, anemia, or neutropenia; dose reduction or discontinuation of interferon and/or ribavirin may be required if toxicity evident.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Zidovudine: Should not use zidovudine in combination with stavudine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300080\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222991\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9946&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Stavudine may enhance the adverse/toxic effect of Didanosine. The risk of lactic acidosis (possibly fatal), hepatomegaly, and pancreatitis may be increased with this combination. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): May diminish the therapeutic effect of Stavudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Liposomal): May diminish the therapeutic effect of Stavudine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxyurea: May enhance the adverse/toxic effect of Stavudine. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist. Stavudine may enhance the adverse/toxic effect of Hydroxyurea. An increased risk of pancreatitis, hepatotoxicity and/or neuropathy may exist.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: May diminish the therapeutic effect of Stavudine.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222993\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223007\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Stavudine has a high level of transfer across the human placenta. No increased risk of overall birth defects has been observed following first trimester exposure to stavudine alone according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Information related to stillbirth, low birth weight, and small for gestational age infants is limited. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>[US Boxed Warning]: Fatal lactic acidosis has been reported in pregnant women using didanosine and stavudine in combination with other antiretroviral agents; co-administration with didanosine is contraindicated.</b> Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In general, NRTIs are well tolerated and the benefits of use generally outweigh potential risk. In addition to lactic acidosis, the combination of didanosine and stavudine has been shown to increase the risk of neurodevelopmental disability.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines do not recommend stavudine for initial therapy in antiretroviral-naive pregnant females due to toxicity; do not use in combination with didanosine or zidovudine. Pharmacokinetics of stavudine are not significantly altered during pregnancy; dose adjustments are not needed. In addition, because of the high risk of toxicity, stavudine should be stopped in females who become pregnant during therapy and women should be switched to a preferred or alternative regimen.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223008\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">Stavudine is present in breast milk; concentrations in breastfeeding infants are negligible.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breastfeeding infants despite maternal therapy. Therefore, in the US, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, females with HIV infection should completely avoid breastfeeding to decrease the potential transmission of HIV (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223009\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be taken without regard to meals. Some products may contain sucrose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222995\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor liver function tests and renal function tests; signs and symptoms of peripheral neuropathy; monitor viral load and CD4 count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222985\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stavudine is a thymidine analog which interferes with HIV viral DNA dependent DNA polymerase resulting in inhibition of viral replication; nucleoside reverse transcriptase inhibitor</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223002\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Penetrates into the CSF achieving 16% to 97% (mean: 59%) of concomitant plasma concentrations; distributes into extravascular spaces and equally between RBCs and plasma </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">V<sub>d</sub>: Children: 0.73 &plusmn; 0.32 L/kg; Adults: 46 &plusmn; 21 L </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Protein binding: Negligible </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Converted intracellularly to active triphosphate form; metabolism of stavudine plays minimal role in its clearance; minor metabolites include oxidized stavudine and its glucuronide conjugate, glucuronide conjugate of stavudine, N-acetylcysteine conjugate of the ribose after glycosidic cleavage </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Capsule and solution are bioequivalent; Children: 76.9%; Adults: 86.4%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: <b>Note: </b>Half-life is prolonged with renal dysfunction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Newborns (at birth): 5.3 &plusmn; 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates 14 to 28 days old: 1.6 &plusmn; 0.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 5 weeks to 15 years: 0.9 &plusmn; 0.3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1.6 &plusmn; 0.2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Intracellular: Adults: 3.5 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine 95% (74% as unchanged drug); feces 3% (62% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223006\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Stavudine Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $365.08</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $379.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $403.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (60): $410.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Zerit Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (60): $491.68</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (60): $511.27</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (60): $543.10</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (60): $553.12</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Zerit Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (200 mL): $102.73</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F223010\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Landstav (MX);</li>\n      <li>Ranstar (MX);</li>\n      <li>Stag-30 (ET);</li>\n      <li>Stavir (IN, LB, TH);</li>\n      <li>Stavmat (ZW);</li>\n      <li>Tonavir (PY, UY);</li>\n      <li>Virostav (MY, UA);</li>\n      <li>Zerit (AR, AT, AU, BB, BE, BG, BH, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HN, HR, HU, ID, IE, IT, KR, KW, LB, LT, LU, LV, MT, MX, NL, NZ, PE, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TR, TW, VE, VN, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al.<i> Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed</i>. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Browne MJ, Mayer KH, Chafee SB, et al, &ldquo;2',3'-Didehydro-3'-deoxythymidine (d4T) in Patients With AIDS or AIDS-Related Complex - A Phase I Trial,&rdquo; <i>J Infect Dis</i>, 1993, 167(1):21-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/8093363/pubmed\" target=\"_blank\" id=\"8093363\">8093363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dudley MN, Graham KK, Kaul S, et al, &ldquo;Pharmacokinetics of Stavudine in Patients With AIDS and AIDS-Related Complex,&rdquo; <i>J Infect Dis</i>, 1992, 166(3):480-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/1323615/pubmed\" target=\"_blank\" id=\"1323615\">1323615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a>. Updated July 14, 2016. Accessed July 13, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf</a>. Updated March 1, 2016. Accessed July 11, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo; <i>Am J Health Syst Pharm</i>, 1998, 55:2528-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/9853641/pubmed\" target=\"_blank\" id=\"9853641\">9853641</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kline MW, Dunkle LM, Church JA, et al, &ldquo;A Phase I/II Evaluation of Stavudine (d4T) in Children With Human Immunodeficiency Virus Infection,&rdquo; <i>Pediatrics</i>, 1995, 96(2 Pt 1):247-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/7630678/pubmed\" target=\"_blank\" id=\"7630678\">7630678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kuhar DT, Henderson DK, Struble KA, et al, &quot;Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis,&quot; <i>Infect Control Hosp Epidemiol</i>, 2013, 34(9): 875-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/23917901/pubmed\" target=\"_blank\" id=\"23917901\">23917901</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lea AP and Faulds D, &ldquo;Stavudine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Clinical Potential in HIV Infection,&rdquo; <i>Drugs</i>, 1996, 51(5):846-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/8861550/pubmed\" target=\"_blank\" id=\"8861550\">8861550</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandstrom E and Oberg B, &ldquo;Antiviral Therapy in Human Immunodeficiency Virus Infections. Current Status,&rdquo; <i>Drugs</i>, 1993, 45(4):488-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/stavudine-drug-information/abstract-text/7684670/pubmed\" target=\"_blank\" id=\"7684670\">7684670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Treatment of Pregnant Women With HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0</a>. Updated November 14, 2017. Accessed December 21, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zerit (stavudine) [prescribing information]. Princeton, NJ: Bristol Myers Squibb; December 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9946 Version 138.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709417\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F223021\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F223022\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F223061\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F223026\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F223044\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F223027\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F223028\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22560126\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222997\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F222982\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F11370380\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F223000\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F222998\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F223069\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222989\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F223003\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222986\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300080\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222991\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F222993\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F223007\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F223008\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F223009\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F222995\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222985\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F223002\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F223006\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F223010\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9946|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=stavudine-patient-drug-information\" class=\"drug drug_patient\">Stavudine: Patient drug information</a></li><li><a href=\"topic.htm?path=stavudine-pediatric-drug-information\" class=\"drug drug_pediatric\">Stavudine: Pediatric drug information</a></li></ul></div></div>","javascript":null}